Associate Professor
Associate Professor (P), Pharmacology and Toxicology, Academic Joint Departments
Associate Professor (S), Dept of Medical Education, School of Medicine
Scientist (C), Center for Clinical and Translational Science (CCTS), General Clinical Research Center
Areas of Interest
Drug metabolism, pharmacokinetics, drug interactions, pharmacometrics, mass spectrometry
Biography
Dr. Fasinu joined the University of Alabama at Birmingham in 2021 as an Associate Professor in the department of Pharmacology & Toxicology. Prior to this, he was an Assistant Professor of Pharmacology at the Campbell university College of Pharmacy and Health Sciences. He obtained his master’s degree in biopharmaceutics from the University of the Witwatersrand before completing his doctorate in pharmacology at the Stellenbosch University. Dr. Fasinu completed a predoctoral fellowship in drug metabolism and pharmacokinetics (DMPK) at the Novartis Institute for Biomedical Research (NIBR), Basel, Switzerland, and later joined the University of Mississippi’s National Center for Natural Products Research (NCNPR) as a postdoctoral research associate. He is a licensed pharmacist in the states of Mississippi, North Carolina, and Alabama, and completed his specialization as a board-certified pharmacotherapy specialist (BCPS).
Dr. Fasinu is invested in translational pharmacology with interest in bench-to-bedside studies. His research is focused on drug metabolism and pharmacokinetics (DMPK) and its application in early-phase clinical trials. In his lab, expertise is built around the application of liver-based technologies for drug biotransformation studies, for elucidating the metabolic pathways of new chemical entities (NCEs), and for drug-drug/ herb-drug interaction studies. Dr. Fasinu conducts pharmacokinetics studies to support investigational new drug (IND) applications and performs analysis of pharmacokinetic data to support new drug applications (NDA). Other research areas of interest for Dr. Fasinu’s lab include pharmacokinetic-pharmacodynamic modeling (PKPD), and pharmacogenetics
Fasinu PS, Chaurasiya ND, Dhammika Nanayakkara NP, Wang YH, Bandara Herath HM, Avula B, McChesney JD, Jollow D, Walker LA, Tekwani BL. Comparative pharmacokinetics and tissue distribution of primaquine enantiomers in mice. Malaria Journal. 2022 Jan; 21(1):1-4.
Khan W, Wang YH, Chaurasiya ND, Nanayakkara ND, Herath HB, Harrison KA, Dale G, Stanford DA, Dahl EP, McChesney JD, Gul W, El-Sohly MA, Khan SI, Fasinu PS, Khan IA, Tekwani BL, Walker LA. Comparative single dose pharmacokinetics and metabolism of racemic primaquine and its enantiomers in human volunteers. Drug Metabolism and Pharmacokinetics. 2022 Aug 1; 45:100463.
Khan W, Wang YH, Nanayakkara ND, Herath HB, Catchings Z, Khan S, Fasinu PS, ElSohly MA, McChesney JD, Khan IA, Chaurasiya ND. Quantitative determination of primaquine-5, 6-ortho-quinone and carboxyprimaquine-5, 6-ortho-quinone in human erythrocytes by UHPLC-MS/MS. Journal of Chromatography B. 2021 Jan 15;1163:122510.
Fasinu PS, Nanayakkara ND, Wang YH, Chaurasiya ND, Herath HB, McChesney JD, Avula B, Khan I, Tekwani BL, Walker LA (2019). Formation of primaquine-5, 6-orthoquinone, the putative active and toxic metabolite of primaquine via direct oxidation in human erythrocytes. Malaria Journal. 2019 Dec;18(1):30.
Sá JM, Kaslow SR, Moraes Barros RR, Brazeau NF, Parobek CM, Tao D, Salzman RE, Gibson TJ, Velmurugan S, Krause MA, Melendez-Muniz V, Kite WA, Han PK, Eastman RT, Kim A, Kessler EG, Abebe Y, James ER, Chakravarty S, Orr-Gonzalez S, Lambert LE, Engels T, Thomas ML, Fasinu PS, Serre D, Gwadz RW, Walker L, DeConti DK, Mu J, Bailey JA, Sim BKL, Hoffman SL, Fay MP, Dinglasan RR, Juliano JJ, Wellems TE (2019). Plasmodium vivax chloroquine resistance links to pvcrt transcription in a genetic cross. Nature Communications. 2019 Sep 20;10(1):1-0.
Fasinu PS, Nanayakkara ND, Wang YH, Chaurasiya ND, Herath HB, McChesney JD, Avula B, Khan I, Tekwani BL, Walker LA (2019). Formation of primaquine-5, 6-orthoquinone, the putative active and toxic metabolite of primaquine via direct oxidation in human erythrocytes. Malaria Journal. 2019 Dec;18(1):30.
Avula B, Tekwani BL, Chaurasiya ND, Fasinu PS, Nanayakkara ND, Herath HB, Wang YH, Bae JY, Khan SI, Elsohly MA, McChesney JD (2018). Metabolism of primaquine in normal human volunteers: investigation of phase I and phase II metabolites from plasma and urine using ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry. Malaria Journal 17(1):294.
Fasinu PS, Manda VK, Dale OR, Egiebor NO, Walker LA, Khan SI (2017). Modulation of Cytochrome P450, P-glycoprotein and Pregnane X Receptor by Selected Antimalarial Herbs— Implication for Herb-Drug Interaction. Molecules. 2017 Nov 23;22(12):2049.
Fasinu P, Choonara YE, Kumar P, du Toit LC, Bijukumar D, Khan RA, Pillay V. Enhancement of the oral bioavailability of felodipine employing 8-arm-poly (ethylene glycol): in vivo, in vitro and in silico evaluation. AAPS PharmSciTech. 2017 Apr 1;18(3):617-28.
Fasinu PS, Tekwani BL, Avula B, Chaurasiya ND, Nanayakkara D, Wang Y, Khan IA, Walker LA (2016). Pathway-specific inhibition of primaquine metabolism by chloroquine/quinine. Malaria J. 15:466.
• Adejumo OE, Kotila, TR, Falusi AG, Silva BO, Nwogu JN, Fasinu PS and Babalola CP (2016). Phenotyping and genotyping of CYP2C19 using comparative metabolism of proguanil in sickle‐cell disease patients and healthy controls in Nigeria. Pharmacology Research & Perspectives,4(5).
Fasinu PS, J Gurley B, A Walker L (2016). Clinically relevant pharmacokinetic herb-drug interactions in antiretroviral therapy. Current drug metabolism. 2016 Jan 1;17(1):52-64.
Fasinu PS, Avula B, Tekwani BL, Nanayakkara NP, Wang YH, Bandara Herath HM, McChesney JD, Reichard GA, Marcsisin SR, Elsohly MA, Khan SI, Khan IA, Walker LA. Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytes. Malaria J. 2016 Apr 19;15(1):224.
Tekwani BL, Avula B, Sahu R, Chaurasiya ND, Khan SI, Jain S, Fasinu PS, Herath HM, Stanford D, Nanayakkara NP, McChesney JD, Yates TW, ElSohly MA, Khan IA, Walker LA. (2015) Enantioselective pharmacokinetics of primaquine in healthy human volunteers. Drug Metab Dispos. 43(4):571-7.
Fasinu PS, Tekwani BL, Nanayakkara NPD, Avula B, Herath BHMT, Wang Y-H, Adelli VR, Elsohly MA, Khan SI, Khan IA, Pybus BS, Marcsisin SR, Reichard GA, McChesney JD, Walker LA. (2014). Enantioselective metabolism of primaquine by human CYP2D6. Malaria Journal 13(1): 507.
Fasinu PS, Bouic P, Rosenkranz B. (2014). The inhibitory activity of the extracts of popular medicinal herbs on CYP1A2, 2C9, 2C19 and 3A4 and the implications for herb-drug interaction. African Journal of Traditional, Complementary and Alternative Medicines (AJTCAM), 11(4), 54-61).
Awortwe C, Fasinu PS, Rosenkranz B. (2014). Application of caco-2 cell line in herb-drug interaction studies: current approaches and challenges. Journal of Pharmacy and Pharmaceutical Sciences, 17(1), 1-19.
Fasinu PS, Heike Gutmann, Hilmar Schiller, Patrick Bouic and Bernd Rosenkranz (2013). The potential of Hypoxis hemerocallidea for herb-drug interaction. Pharmaceutical Biology 51(12), 1499- 1507.
Fasinu PS, Gutmann H, Schiller H, James AD, Bouic P, Rosenkranz B. (2013). The potential of Sutherlandia frutescens for herb-drug interaction. Drug Metabolism and Disposition; 2013 Feb;41(2):488-97. doi: 10.1124/dmd.112.049593.
Fasinu PS, Choonara YE, du Toit LC, Kumar P, Ndesendo VMK, Khan RA, Pillay V. (2013). Flavonoids and polymer derivatives as CYP3A4 inhibitors for improved oral drug bioavailability: An in vitro and in silico comparative analysis. Journal of Pharmaceutical Sciences; 102(2):541-55.
Fasinu PS, Bouic PJ, Rosenkranz B. (2013). An overview of the Evidence and mechanisms of herb– drug interactions. Front.Pharmacol. 3:69. doi:10.3389/fphar.2012.00069.
Fasinu PS, Bouic PJ, Rosenkranz B. (2012). Liver-based in vitro technologies for drug biotransformation studies – a review. Current Drug Metabolism; 13:215-224.
Fasinu PS, Pillay V, Ndesendo V, du Toit L, Choonara Y. (2011). Diverse approaches for the enhancement of oral drug bioavailability. Biopharmaceutics and Drug Disposition; 32:185-209.
Education
MSc (Med) - University of the Witwatersrand, Johannesburg, South AfricaPostdoctoral Fellowships
Ph.D. - Division of Clinical Pharmacology, Stellenbosch University, South Africa
Postdoctoral Fellow, National Center for Natural Products Research, University of Mississippi
Board Certified Pharmacotherapy Specialist, American Board of Pharmacy Specialties
Contact
Office Location
Volker Hall 254
Phone
205-934-4565
Email
pfasinu@uab.edu